Re-positioning of FDA-Approved Compounds in MPS III Cell ModelsCure Sanfilippo Foundation is funding search to explore re-positioning FDA-approved compounds using cell-based, high-content screening in Sanfilippo Syndrome (MPS III) cell models.
Awardee: Diego Medina, PhD- Telethon Institute of Genetics and Medicine (TIGEM)- Italy
Start Date: June 2018
UPDATE: October 2019
In October 2019, TIGEM presented preliminary results of this study at the Conference of Telethon Fundamental Associations in Italy. Read more.